Exscientia plc has described NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, autoimmune disease, cancer, gout, inflammatory and neurological disorders, psoriasis and sickle cell disease.
Alterome Therapeutics Inc. has divulged RAC-α serine/threonine-protein kinase (AKT1; PKBα) (E17K mutant) inhibitors reported to be useful for the treatment of cancer.
Chiesi Farmaceutici SpA has synthesized heterocyclic derivatives acting as Janus kinase (JAK) inhibitors reported to be useful for the treatment of acute lung injury, asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
Tibet Haisco Pharmaceutical Co. Ltd. has disclosed integrin α4β7 (LPAM-1) and/or α4β1 (ITGA4; VLA-4) antagonists reported to be useful for the treatment of inflammatory disorders.
Yes, even a phase III protocol for a “failed” trial can constitute prior art, the U.S. Court of Appeals for the Federal Circuit told a lower court April 1 when it returned Janssen Pharmaceuticals Inc. and Teva Pharmaceuticals USA Inc.’s patent squabble for a do-over.
Dizal (Jiangsu) Pharmaceutical Co. Ltd. has described EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer and autoimmune disease.
Nectin Therapeutics Ltd. has divulged antibody-drug conjugates (ADCs) comprising a humanized monoclonal antibody targeting poliovirus receptors (PVR; CD155) linked to a cytotoxic drug through a linker. They are reported to be useful for the treatment of cancer.
Grafton Therapeutics Sarl has identified halogenated somatostatin analogues acting as somatostatin SST2 receptor and/or SST5 receptor agonists reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has synthesized ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and neurodegeneration.
RSS